Education
About Us
Working with TipRanks
Follow Us
Unicycive Therapeutics, Inc. (UNCY)
:UNCY
UNCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.20 - $1.29
Previous CloseN/A
Volume1.16M
Average Volume (3M)1.07M
Market Cap
$65.55M
Enterprise Value$65.04M
Total Cash (Recent Filing)$24.33M
Total Debt (Recent Filing)$991.00K
Price to Earnings (P/E)―
Beta1.13
Next Earnings
May 20, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding119,705,025
10 Day Avg. Volume1,623,615
30 Day Avg. Volume1,067,003
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)114.16
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit96.36
Enterprise Value/Ebitda-1.64
Forecast
1Y Price Target
$5.83Price Target Upside960.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalOLC's FDA approval is expected by its PDUFA date, affirming a buy recommendation.
Market ConditionsThe anticipated FDA approval and commercial launch of OLC will coincide with favorable market conditions due to the expansion of Medicare patient access to phosphate binders.
Market OpportunityOLC's potential to attain pricing similar to the leading branded drug in the category, Fosrenol, suggests a significant market opportunity.
Bears Say
Clinical Trial TolerabilityIn the MAD portion, the side effects in the 40mg cohort included headache, nausea, and vomiting. Only one participant dropped out of the study. In the 80mg cohort, four participants dropped out and it was not considered well-tolerated.
Product TolerabilityMost side effects in the SAD portion were mild. Headache was the most reported side effect, and all participants completed the study.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
UNCY FAQ
What was Unicycive Therapeutics, Inc.’s price range in the past 12 months?
Unicycive Therapeutics, Inc. lowest stock price was $0.20 and its highest was $1.29 in the past 12 months.
What is Unicycive Therapeutics, Inc.’s market cap?
Unicycive Therapeutics, Inc.’s market cap is $65.55M.
When is Unicycive Therapeutics, Inc.’s upcoming earnings report date?
Unicycive Therapeutics, Inc.’s upcoming earnings report date is May 20, 2025 which is in 36 days.
How were Unicycive Therapeutics, Inc.’s earnings last quarter?
Unicycive Therapeutics, Inc. released its earnings results on Mar 31, 2025. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of -$0.074 by $0.324.
Is Unicycive Therapeutics, Inc. overvalued?
According to Wall Street analysts Unicycive Therapeutics, Inc.’s price is currently Undervalued.
Does Unicycive Therapeutics, Inc. pay dividends?
Unicycive Therapeutics, Inc. does not currently pay dividends.
What is Unicycive Therapeutics, Inc.’s EPS estimate?
Unicycive Therapeutics, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Unicycive Therapeutics, Inc. have?
Unicycive Therapeutics, Inc. has 119,705,025 shares outstanding.
What happened to Unicycive Therapeutics, Inc.’s price movement after its last earnings report?
Unicycive Therapeutics, Inc. reported an EPS of $0.25 in its last earnings report, beating expectations of -$0.074. Following the earnings report the stock price went down -6.557%.
Which hedge fund is a major shareholder of Unicycive Therapeutics, Inc.?
Among the largest hedge funds holding Unicycive Therapeutics, Inc.’s share is RA Capital Management. It holds Unicycive Therapeutics, Inc.’s shares valued at 0.
---
Unicycive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.83 (960.00% Upside)
$5.83 (960.00% Upside)
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-56.24%
12-Months-Change
Fundamentals
Return on Equity
-2355.27%
Trailing 12-Months
Asset Growth
123.16%
Trailing 12-Months
Company Description
Unicycive Therapeutics, Inc.
Unicycive Therapeutics (UNCY) is a biopharmaceutical company focused on developing novel treatments for kidney diseases. The company operates within the healthcare sector, specifically targeting nephrology. Its core products include innovative therapies aimed at addressing unmet medical needs in patients suffering from chronic kidney diseases and related conditions.
---
UNCY Stock 12 Month Forecast
Average Price Target
$5.83
▲(960.00% Upside)
Technical Analysis
Alkermes
―
BioCryst
―
Corbus Pharmaceuticals
―
Akari Therapeutics
―
Atea Pharmaceuticals
―
Best Analysts Covering UNCY
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+1.40%
reiterated a buy rating 14 days ago
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +1.40% per trade.
---